P5L mutation in Ank results in an increase in extracellular inorganic pyrophosphate during proliferation and nonmineralizing hypertrophy in stably transduced ATDC5 cells
© Zaka et al.; licensee BioMed Central Ltd. 2006
Received: 10 August 2006
Accepted: 26 October 2006
Published: 26 October 2006
Ank is a multipass transmembrane protein that regulates the cellular transport of inorganic pyrophosphate. In the progressive ankylosis (ank) mouse, a premature termination mutation at glutamic acid 440 results in a phenotype characterized by inappropriate deposition of basic calcium phosphate crystals in skeletal tissues. Mutations in the amino terminus of ANKH, the human homolog of Ank, result in familial calcium pyrophosphate dihydrate deposition disease. It has been hypothesized that these mutations result in a gain-of-function with respect to the elaboration of extracellular inorganic pyrophosphate. To explore this issue in a mineralization-competent system, we stably transduced ATDC5 cells with wild-type Ank as well as with familial chondrocalcinosis-causing Ank mutations. We evaluated the elaboration of inorganic pyrophosphate, the activity of pyrophosphate-modulating enzymes, and the mineralization in the transduced cells. Expression of transduced protein was confirmed by quantitative real-time PCR and by ELISA. Levels of inorganic pyrophosphate were measured, as were the activities of nucleotide pyrophosphatase phosphodiesterase and alkaline phosphatase. We also evaluated the expression of markers of chondrocyte maturation and the nature of the mineralization phase elaborated by transduced cells. The cell line expressing the proline to leucine mutation at position 5 (P5L) consistently displayed higher levels of extracellular inorganic pyrophosphate and higher phosphodiesterase activity than the other transduced lines. During hypertrophy, however, extracellular inorganic pyrophosphate levels were modulated by alkaline phosphatase activity in this cell system, resulting in the deposition of basic calcium phosphate crystals only in all transduced cell lines. Cells overexpressing wild-type Ank displayed a higher level of expression of type X collagen than cells transduced with mutant Ank. Other markers of hypertrophy and terminal differentiation, such as alkaline phosphatase, osteopontin, and runx2, were not significantly different in cells expressing wild-type or mutant Ank in comparison with cells transduced with an empty vector or with untransduced cells. These results suggest that the P5L Ank mutant is capable of demonstrating a gain-of-function with respect to extracellular inorganic pyrophosphate elaboration, but this effect is modified by high levels of expression of alkaline phosphatase in ATDC5 cells during hypertrophy and terminal differentiation, resulting in the deposition of basic calcium phosphate crystals.
The pathologic deposition of calcium pyrophosphate dihydrate crystals in the joints of patients with familial chondrocalcinosis is associated with mutations in ANKH (for a review, see ). The ANKH gene is the human homologue of the gene responsible for progressive ankylosis in a naturally occurring mutant mouse . The product of the ank/ANKH gene appears to regulate the transport of inorganic pyrophosphate (PPi) through the cell membrane. Sohn and colleagues originally observed high expression of Ank in the hypertrophic growth plate . Interestingly, high levels of ANKH expression have also been found in osteoarthritic cartilage and in cartilage from patients with calcium pyrophosphate dihydrate deposition (CPPD), particularly in areas of cartilage tissue that are populated with hypertrophic-like chondrocytes [4–6]. While these observations suggest that Ank plays a role in the pathological mineralization of cartilage, Wang and colleagues  have shown that the protein also has an important role in the physiological mineralization of the chick tibial growth plate by demonstrating that increased Ank activity led to decreased levels of extracellular PPi resulting from the concomitant upregulation of alkaline phosphatase (AP) expression.
To characterize the role of wild-type Ank and its mutants in the regulation of PPi transport in vitro, we stably transduced ATDC5 cells with wild-type Ank and three missense mutations we have reported in families with familial chondrocalcinosis. We chose to only modestly overexpress wild-type and mutant Ank in order to create a stable dominant-negative environment in which to evaluate PPi elaboration, as well as the activity of two enzymes that are critical to the fate of PPi generation: nucleotide pyrophosphohydrolase phosphodiesterase (NPP) and AP. These studies were performed in ATDC5 cells to take advantage of the fact that these well-characterized cells are fully mineralization competent  and are amenable to stable transfection. Furthermore, the use ofATDC5 cells permitted us to address some critical issues concerning the biochemical and physiological impact of overexpression of wild-type Ank, and the expression of mutant forms of Ank, on the course of chondrogenesis.
Materials and methods
Cell culture, proliferation assays, and gene expression studies
ATDC5 cells  (3 × 104 cells/35 mm dish) were maintained in DMEM/Ham's F-12 (1:1) containing 5% fetal bovine serum, 2 mM L-glutamine, 10 μg/ml human transferrin, and 3 × 10-8 M sodium selenite (maintenance medium), or the cells were differentiated, without passage, in the same medium supplemented with 10 μg/ml insulin (chondrogenic medium). The media were changed every other day. Proliferation of untransduced cells or transduced cells was monitored using the cell proliferation agent WST-1 (Roche, Indianapolis, IN, USA). Cells were propagated in 96-well plates at the same cell density as described above. Following addition of WST-1 reagent, the optical density was read at 450 nm. The background was determined by assay of clean media collected at equivalent time points.
For studies of mineralization in ATDC5 cells, at day 21 of culture, α-MEM medium containing 5% fetal bovine serum 2 mM glutamine, 10 μg/ml human transferrin, 3 × 10-8 M sodium selenite, and 10 μg/ml insulin was added to the cell cultures without passage of cells. The concentration of CO2 was also switched to 3%, as previously described . The medium was replaced every other day. For measurements of mineral content by Fourier transform IR analyses, cell layers were washed with phosphate-buffered saline, scraped into 0.1 M ammonium bicarbonate solution (pH 8.5), pelleted, and lyophilized.
For experiments in which the constitutive expression of ank was assessed, cells were incubated in parallel cultures containing maintenance medium and chondrogenic medium for a period of 21 days. Cells were harvested at the times indicated above for poly A+ RNA isolation using the Micro-FastTrack 2.0 kit according to manufacturer's specifications (Invitrogen, Carlsbad, CA, USA). For cDNA synthesis, 150 ng mRNA was reverse transcribed using the ThermoScript RT-PCR system (Invitrogen). The resultant cDNA was utilized for quantitative RT-PCR, using β-actin as standard. The primers used to amplify ank were sense primer 5' -cttctagcagggtttgtggg-3' (in exon 11 of the transcript) and antisense primer 5' -tcgtctctttcctcctcctc-3' (in the 3' -untranslated region; product = 166 bp). Thermocycling was performed in a MyIQ thermocycler (Biorad, Hercules, CA, USA) using a reaction mix containing syber green. A melting curve was performed for each PCR cycling reaction to ensure recovery of a single syber green fluorescing species in the reaction product. The fold changes of steady-state RNA levels were determined by the formula 2-ddCt, where ddCt = dE – dC (dE = Ctexp – Ctactin and dC = Ctcontl – Ctactin; dE = delta experimental, dC = delta control, Ct = cycling threshold).
Preparation of FLAG-tagged Ank constructs and transient transfection with FLAG-tagged constructs
The wild-type sequence of murine ank was used for both transient and stable cDNA constructs of ank, and all mutations in ank were prepared in the context of the mouse cDNA sequence. Ank cDNA was subcloned into a pcDNA I vector (Invitrogen) containing a FLAG sequence at the amino terminus of the multiple cloning site. To generate an inframe FLAG tag, the stop codon of each Ank cDNA – wild type and the proline position 5 to leucine (P5L), proline position 5 to threonine (P5T), and methionine position 48 to threonine (M48T) mutants – was ablated by site-directed mutagenesis and the FLAG tag was added to the 3' end of each cDNA by the PCR. The integrity of each construct was confirmed by direct sequence analysis of the entire cDNA-FLAG insert.
For transfection with pcDNA I/ank-FLAG cDNA constructs, ATDC5 cells were transfected with wild-type and mutant constructs (1 μg plasmid DNA/ml medium) in the presence of FuGene 6 reagent (Roche) at a ratio of 1 μg plasmid DNA:2.5 μl FuGene 6 reagent. A construct containing the lacZ gene was prepared as a control for transfection efficiency using the same lacZ:FuGene6 ratio. After 48 hours of culture in maintenance medium, cells were fixed with 4% p-formaldehyde and were immediately processed for immunohistochemistry using a mouse polyclonal anti-FLAG M2 antibody (Stratagene, La Jolla, CA, USA). and goat anti-mouse secondary IgG antibody conjugated to Alexa fluor 488 (Molecular Probes, Eugene, OR, USA). Parallel chamber slides were incubated in secondary antibody only. Cells were mounted with VectaShield (Vector Laboratories, Inc., Burlingame, CA, USA) mounting medium with propidium iodide for fluorescent detection of double-stranded DNA, and the cells were then visualized on a Zeiss LSM510 Mera confocal microscope (Carl Zeiss MicroImaging, Thornwood, NY, USA) using a 63x lens.
Preparation of retroviral Ankconstructs and stable transduction of ATDC5 cells
For the preparation of stable transfections via retroviral transduction, ank cDNA wild-type and mutant constructs, prepared in the context of the mouse cDNA sequence, were subcloned into the pLNCX expression vector (Clontech, Palo Alto, CA, USA) and were packaged as directed by the manufacturer. Virus-containing medium was directly added to ATDC5 cells that had been plated to 80% confluence in maintenance medium 24 hours prior to infection. After 24 hours cells were subjected to selection with the neomycin resistance reagent G418 (350 μg G418/ml media) for 2 weeks (media were changed every 4 days). Approximately 10% of cells survived selection and were expanded at low density in 100 μg G418/ml media and were further subjected to clonal selection. Cells were expanded in the presence of G418 to ensure retention of the transduced cDNAs, and were eventually harvested for mRNA isolation to evaluate relative expression of endogenous and transduced cDNAs.
DNA was also isolated and used in Southern blot analyses to confirm the clonality of the cell lines. Genomic DNA was cleaved with XbaI (an enzyme that cleaves only once in the pLNCX vector in the 3' long terminal repeat region), blotted, and probed with a PCR product derived from the cytomegalovirus promoter region of the pLNCX vector to exclude detection of endogenous ank sequences.
Detection of expression of transduced Ank in ATDC5 cells by real-time PCR
Real-time PCR was used to measure levels of both endogenous and transduced ank transcripts in clonally selected populations. For detection of transduced wild-type or mutant ank transcripts, PCR primers were derived from sequences between exons 11 and 12 of the ank cDNA (sense primer, 5' -ggtttgtgggagaatctacc-3'); the antisense primer was derived from the pLNCX vector (5' -ccccctttttctggagacta-3' ; product size = 265 bp). For detection of endogenous ank transcript, the primers described earlier in Materials and methods were used. The ratio of PCR products was determined by comparison of the ddCt values for the endogenous transcript divided by the ddCt for the transduced transcript, as previously described. For each cloned transductant, four separate clones expressing a 1:1 ratio of endogenous to transduced transcript were independently evaluated for Ank protein expression.
ELISA determination of Ank protein expression in stably transduced cells
Cells were harvested, in the presence of protease inhibitor, from confluent cultures of transduced cells and were disrupted by rapid freeze/thaw with final dispersion through an 18-gauge needle. Protein was quantitated by the Bradford Coomassie assay (Pierce, Rockford, IL, USA), using bovine serum albumin as the standard.
Polyclonal anti-Ank antisera were generated (Cocalico, Biologicals Inc., Westville, PA, USA) in Leghorn chickens against a synthetic peptide immunogen derived from the Ank carboxy terminus conjugated to keyhole limpet hemocyanin, as previously described  for the preparation of an Ank-specific antiserum. Ammonium sulfate-precipitated chicken antibody derived from blood sera was delipidated with n-butanol/diisopropyl ether in a 40:60 (vol/vol) ratio .
ELISA procedures relevant to the determination of antibody or antigen titers using a twofold dilution series have been described . Primary antibody binding to antigens was detected with an affinity-purified, peroxidase-conjugated donkey anti-chicken IgY (Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA) at a dilution of 1:5,000. The secondary antibody was then quantitated with a chromogenic substrate, o-phenylenediamine, and the optical densities at 490 nm were recorded with a microplate reader (Opsis MR Microplate Reader; Thermo/Labsystems, Waltham. MA, USA) using Revelation Quicklink software (Dynex Technologies, Chantilly, VA, USA).
Intracellular and extracellular inorganic pyrophosphate assays
For studies of extracellular inorganic pyrophosphate (ePPi) and intracellular inorganic pyrophosphate (iPPi) elaboration in cells undergoing differentiation, as well as for measurements of AP and NPP activities, and measurement of expression of markers of hypertrophy (see below), cells were cultured in differentiation medium until 24 hours prior to assay. At this time, media for cells to be assayed were refreshed with maintenance medium (which does not contain insulin).
For assay of iPPi, cells were harvested heated at 65°C for 1 hour and were lysed in lysis buffer containing 1% Triton X-100, 1.6 mM MgCl2, and 0.2 M Tris, pH 8.0. For assay of ePPi, media were cleared of cellular debris and were diluted 1:2 in lysis buffer. PPi levels were evaluated by the enzymatic procedure of Lust and Seegmiller , as modified by Johnson and colleagues , where PPi is determined by differential absorption on activated charcoal of UDP-D- [6-3H]-glucose from the reaction product 6-phospho- [6-3H]-gluconate. All assay results were normalized versus DNA concentration using a Pico Green assay of double-stranded DNA (Molecular Probes).
Assays of alkaline phosphatase and nucleotide pyrophosphohydrolase activity
The diethanolamine enzymatic assay (Sigma, St Louis, MO, USA) was used to measure the AP (EC 18.104.22.168) activity . Cells were disrupted, were reacted with substrate solution containing a final concentration of 15 mM p-nitrophenyl phosphate in the presence of 1 M diethanolamine and 0.5 mM MgCl2, pH 9.8, and the optical densities of the reaction product (p-nitrophenol) were determined at 405 nm at time 0 and at 1 and 2 minutes after the start of the reaction. The AP activity was normalized to the total protein concentration of diluted cell lysates as determined by use of the BCA Protein assay (Pierce). Inhibition of AP activity was performed with the addition of 3 μM levamisole, which was added to the cell culture medium for 72 hours prior to harvesting for AP activity measurements.
For the assay of NPP (EC 22.214.171.124, EC 126.96.36.199) activity, 1 mM p-nitrophenyl-thymidine 5' -monophosphate (Sigma) was used as substrate in a reaction to which 5 μl cell lysate was added . A standard curve consisting of p-nitrophenol in 50 mM Hepes-buffered DMEM and 1.6 mM MgCl2 was also prepared. Reactions were terminated by the addition of 55 μl of 0.1 M NaOH, and optical densities were determined at 405 nm. Final sample comparisons were expressed as units per milligram of total protein.
Expression of markers of chondrocyte maturation and terminal differentiation
To monitor the differentiation of transduced cells, poly A+ RNA was used in real-time RT-PCR to detect the expression of type II collagen (col2a1), of sox9, and of type X collagen (col10a1). Primers for these transcripts were as follows: col2a1, sense primer 5' -gagggccaggaggtcctctgg-3' and antisense primer 5' -tcgcggtgagccatgatccgc-3' (product size = 177 bp); col10a1, sense primer 5' -taccacgtgcatgtgaaagg-3' and antisense primer 5' -ggagccactaggaatcctga-3' (product size = 236 bp); and sox9, sense primer 5' -agt tga tct gaa gcg aga ggg-3' and antisense primer 5' -cct ggg tgg ccg ttg ggt ggc-3' (product size = 169 bp).
Expression levels of additional markers of the hypertrophic phenotype were measured to evaluate the impact of ank mutants on hypertrophy in transduced ATDC5 cells. These additional markers included osteopontin (sense primer 5' -cac atg aag agc ggt gag tct-3', antisense primer 5' -atc gat cac atc cga ctg atc-3' ; product size = 198 bp) and runx2 (cbfa1; sense primer 5' -atggcactctggtcaccgtc-3', antisense primer 5' -cctgaggtcgttgaatctcg-3' ; product size = 110 bp).
The fold changes of steady-state RNA levels in ank-transduced cells compared with cells transduced with empty vector only were determined as previously described. Reactions were performed in triplicate and were repeated twice.
Data are presented as the mean ± standard deviation. The statistical significance was identified using the unpaired, two-tailed Student t test, unless otherwise indicated in the figure legend (P values reported in the figure legends). All assays were performed at least in triplicate; see figure legends for the exact number of replicates performed.
Expression of endogenous ankin ATDC5 cells
Before transduction studies were performed, we determined the endogenous expression of ank in the cell line during a 21-day course of chondrogenesis, prior to the entry of cells into hypertrophy. Cells were plated in the presence or absence of the chondrogenic promoter insulin  and mRNA was isolated for determination of ank expression., The expression of ank after day 3 of culture was consistent throughout the proliferation stage in the untransduced cells regardless of the insulin treatment regimen (data not shown).
Localization of mutant Ank molecules to the cell membrane
Selection and characterization of clonal populations of ATDC5 cells expressing wild-type and mutant Ank
To achieve moderate levels of mutant ank expression in ATDC5 cells that were comparable with expression of the endogenous transcript, we chose to subject our transduced cells to a further round of selection using limiting dilution. Clonality was confirmed by Southern blot analysis (data not shown), and mRNA was isolated and subjected to real-time RT-PCR with primers specific for either the transduced ank transcripts or the endogenous ank transcripts. The clones were then analyzed for both endogenous and exogenous ank transcript levels, and clones that exhibited a 1:1 ratio of endogenous transcript to transduced transcript were selected for further analysis. For each wild-type or mutant construct, four independent clones exhibiting a 1:1 ratio of transduced to endogenous transcript were assayed for protein expression.
To ensure that transduced cells were expressing gene product derived from the transduced cDNAs, we first considered the possibility of adding a tag to the transduced cDNAs to follow their expression and translation into protein. We ultimately wished to use the transduced cell lines for determination of PPi levels, however, and we were acutely aware of the fact that minor perturbations in the structure of the Ank protein can have a major impact on Ank function [2, 15, 16, 18, 19]. We therefore chose to monitor the production of total Ank protein by a quantitative ELISA assay using a peptide-directed polyclonal antibody that was capable of reacting to exposed (that is, nontransmembrane) epitopes following cell disruption. We expected clones expressing a 1:1 ratio of endogenous ank transcript to transduced ank transcript to produce approximately twice the amount of Ank protein as cells that expressed endogenous ank transcript only. ELISA assays were performed on the cell lines, and the results indicated that clones transduced with wild-type or mutant ank expressed approximately twice the level of Ank protein as observed in the original, untransduced cells (Figure 1b).
To determine whether transduction of wild-type and mutant ank constructs affected proliferation of transduced cells, we determined the proliferation and cell viability based upon the cleavage of the tetrazolium salt, WST-1, by mitochondrial dehydrogenases in viable cells. At days 7, 14, and 21 of assay there were no significant statistical differences in proliferation and viability in cells transduced with wild-type ank or mutant ank compared with cells transduced with empty vector (Figure 1c). These results demonstrated that the transduction of ank did not affect the ability of cells to proliferate normally.
Levels of intracellular and extracellular inorganic pyrophosphates in transduced ATDC5 cells
In light of reports suggesting that Ank expression is increased in regions of cartilage undergoing terminal differentiation and mineralization, or in response to agents that induce mineralization [3, 6, 7], we explored the possibility that the high levels of ePPi in mineralized cells might be a function of increased Ank expression. Figure 3d illustrates that ank expression is roughly equivalent among the cells lines transduced with wild-type or mutant ank at all three stages of chondrogenesis; however, the expression of ank in the transductants increased as the cells progressed toward mineralized hypertrophy. Notably, there was an approximately fourfold increase in ank expression in the transduced cells at mineralized hypertrophy compared with that in nonmineralized hypertrophic cells. As illustrated in Figure 3c, in mineralizing conditions we did not observe a statistically significant increase in ePPi in any of the mutant cell lines, including the P5L cell line, when compared with cells transduced with wild-type ank. Additionally, there was no statistically significant difference in the elaboration of ePPi in cells that overexpressed wild-type Ank compared with cells transduced with empty vector only.
Our observations were consistent with the previous observations of Wang and colleagues , although not as dramatic as those they observed. More specifically, Wang and colleagues observed that retroviral-driven overexpression of Ank in hypertrophic chondrocytes actually decreased the elaboration of ePPi, apparently due to increased activity of AP resulting from the overexpression of Ank (see below), while, as stated above, we observed that modest overexpression of Ank did not result in an increase in the elaboration of ePPi compared with cells transduced with empty vector only. Since ATDC5 cells have been shown to elaborate significant amounts of AP during their mineralization phase , we hypothesized that the lack of ePPi excess in cells overexpressing Ank compared with that in cells transduced with empty vector, or in the P5L mutant cell line, may be due to hydrolysis of PPi by AP. We therefore next evaluated the nature of PPi elaboration at hypertrophy and at mineralization as a function of AP activity, as well as of NPP activity.
Alkaline phosphatase and nucleotide pyrophosphohydrolase activity activities in ATDC5 cells transduced with wild-type and mutant Ank
In the complex regulation of cellular PPi elaboration, two major enzyme systems play an important role in the generation of extracellular PPi: NPP, an ecto-enzyme that can hydrolyze nucleoside triphosphates into their monophosphate esters and PPi; and AP, an enzyme with pyrophosphatase activity . We evaluated the levels of both of these enzymes in transduced cells during the proliferative phase of differentiation (day 14), the nonmineralizing hypertrophic phase of differentiation (day 28), and the mineralization phase of differentiation (day 35).
Activities of the PPi-generating enzyme NPP were also evaluated in proliferating cells, in the nonmineralizing, hypertrophic cells, and in mineralizing cells that had been transduced with wild-type and mutant ank at days 14, 28, and 35, respectively. Figure 4 demonstrates that, in contrast to cells transduced with wild-type ank and the P5T mutant and M48T mutant Ank, the P5L mutant cell line consistently exhibited significantly higher NPP activity during the proliferative, the nonmineralizing hypertrophic, and the mineralization phases of differentiation. All of the transduced cells illustrated an increase in NPP activity at day 35 (mineralization) of culture; this observation was consistent with previous reports showing that an increase in AP expression leads to enhanced levels of PC-1, an NPP isoform .
Taken together, our data suggest that at day 35 (mineralizing hypertrophy) neither NPP nor AP are entirely responsible for the high levels of ePPi elaboration among the ank-transduced cell lines (Figure 3c), including the P5L cell line. Rather, the results strongly suggest that the increase in ePPi elaboration in the ank-transduced cells during the mineralizing hypertrophic stage of chondrogenesis at day 35 is a reflection of the increase in transport activity of Ank (that is, higher levels of ank expression).
Effect of ank overexpression, and expression of mutant ankon the hypertrophic phenotype in transduced ATDC5 cells
Since studies of idiopathic CPPD disease have suggested that the pathological mineralization of articular cartilage may occur in a matrix that expresses many markers of chondrocyte hypertrophy [5, 25], we took advantage of the fact that ATDC5 cells are capable of undergoing a complete course of chondrocyte maturation that would enable us to monitor the course of chondrogenesis in the ank-transduced cells. As reported previously , the synthesis of col2a1 reached maximal levels at day 14 of culture. At 28 days of culture, all cells – whether transduced with empty vector, with wild-type Ank, or with mutant Ank – were morphologically hypertrophic and exhibited a decrease in col2a1 and sox9 expression levels compared with the levels observed in transduced cells at their proliferative phase (data not shown), with a comcomitant increase in expression of col10a1 that peaked at 35 days of culture . These observations showed that stably transduced cells were fully competent to appropriately undergo a course of chondrogenesis, thus indicating that retroviral transduction did not influence the course of chondrogenic differentiation in the cells.
Mineralization in ATDC5 cells transduced with wild-type and mutant ank
To determine whether transduced cells cultured under mineralizing conditions were competent to undergo mineralization, cells were cultured in a mineralization medium in 3% CO2 (see Materials and methods)as previously described . At 35 days of culture, the cells were then processed for analysis of the nature of the mineral phase deposited by all cell lines, including cells expressing mutant Ank molecules. Similar to the cells overexpressing wild-type Ank, the mineral to matrix ratio for cells expressing mutant Ank molecules exhibited low crystallinity compared with those cells transduced with empty vector only (data not shown). In all cases, however, Fourier transform IR analyses of the mineral phase indicated that only basic calcium phosphate was deposited. This finding is probably a result of the high AP activity in the cell lines during mineralization. With respect to the P5L cell line, the hydrolysis of the NPP-driven excess in ePPi by AP is probably also responsible for the deposition of basic calcium phosphate in this cell line.
Recent studies of Ank in a variety of model systems have suggested that the expression of Ank is intimately involved in the regulation of cartilage mineralization and that, at the very least, this regulation includes a triad of constituents: Ank, AP, and isoforms of nucleotide NPP, especially the NPP1 isoform (for a review, see ). Human ANK and murine Ank exhibit almost 98% homology at the protein level, with complete conservation of charge and polarity among substituted residues. For this reason, we decided to utilize a mouse cell line for our studies and to prepare mutations in ank in the context of the mouse cDNA sequence. Use of the ATDC5 cell line also enabled us to evaluate the effect of overexpression of Ank and expression of mutant Ank on hypertrophy – a point of interest in light of the fact that Uzuki and colleagues recently observed that ANKH immunoreactivity in chondrocytes derived from patients with idiopathic CPPD disease reached maximum levels in areas of affected articular cartilage occupied by chondrocytes exhibiting expression of markers of hypertrophy .
In the studies described herein, we chose to only modestly overexpress wild-type and mutant Ank in order to create a stable dominant-negative environment in which to evaluate PPi elaboration, to evaluate AP and NPP activity, and to evaluate expression of markers of hypertrophy in transduced cells. PPi analyses in the Ank mutants indicated that only the P5L mutant generated more ePPi than any other mutant or wild-type Ank transduced cells at the proliferative and nonmineralizing hypertrophic stages of differentiation. This line also consistently displayed greater NPP activity at all stages of maturation than any other cell line. Our studies suggest that the increase in ePPi in the P5L cell line is probably a direct reflection of the NPP activity exhibited by this mutant. These observations are consistent with previous studies showing that Ank regulates PPi levels in coordination with the PPi-generating activity that is specifically contributed by NPP1 . The P5L mutation is unique among the two proline mutations at the 5 position studied here – in that the proline residue is substituted with a neutral, nonpolar amino acid, in contrast to the P5T mutant in which proline is substituted with a polar residue. How this fact may affect the structure of the P5L mutant Ank is presently unclear and must await the studies of Ank transmembrane topology that are currently underway in our laboratory.
We also investigated the steady-state mRNA expression of several hypertrophy-related genes in our ATDC5 cells transduced with wild-type and mutant ank. While the course of differentiation appeared to be undisturbed with regard to expression of markers of chondrocyte proliferation and differentiation such as sox9 and col2a1, we were able to observe subtle differences in the expression of col10a1 in the transduced cells that overexpressed wild-type ank. Under nonmineralizing hypertrophic conditions, cells overexpressing wild-type ank demonstrated levels of expression of col10a1 that were twofold to threefold higher than levels in cells transduced with empty vector only. Cells expressing mutant Ank constructs, however, did not exhibit any significant change in expression of col10a1 when compared with cells transduced with empty vector.
Previous in vitro studies of the impact of dominant mutations in ANKH on the function of the ANK protein were performed on transfected COS cells with constructs containing the insertion of four amino acids mutant and the M48T mutant . The familial mutations did not significantly alter iPPi levels, and ePPi levels were not examined. To explain the lack of impact on iPPi observations, it was hypothesized that, in contrast to the ank/ank recessive mouse mutant, the dominant human CPPD disease mutations might act as gain-of-function alleles that would moderately increase ePPi levels over time, leading to subtle abnormalities that have a minor and cumulative impact on articular cartilage homeostasis .
Recent studies of transient transfection of a familial (P5L ) ANKH mutation and two ANKH variants (-4 bp, 5' untranslated region  and deletion of E490 ) in an immortalized human chondrocyte cell line (CH-8) demonstrated an increase in the transcription and translation of ANK. Among the two missense ANKH mutants studied, neither the P5L mutant nor the M48T mutant demonstrated an increase in ePPi elaboration . This effect may, in part, be due to the fact that the studies were performed in an immortalized cell line of human articular chondrocytes that elaborates large amounts of tumor necrosis factor alpha , a cytokine reported to inhibit the elaboration of PPi in articular chondrocytes and cartilage explants  and shown to dramatically decrease the expression of ank mRNA in cultured rat chondrocytes . Interestingly, this same study explored the expression of type X collagen in order to determine whether ANKH variants had the potential to stimulate hypertrophic differentiation in the transfected immortalized articular chondrocytes. Only those cells expressing the P5L variant appeared to induce the expression of type X collagen . Our observations of type X collagen expression show that, among the mutant constructs expressed in transduced cells, the P5L mutant cell line showed the highest level of type X collagen expression; however, all mutant cell lines expressed considerably less col10a1 than did cells overexpressing wild-type ank.
While the various in vitro studies of Ank overexpression on PPi transport activity consistently demonstrate an increase in ePPi levels (or a decrease in iPPi levels) [2, 6, 7, 15, 31], there is a notable lack of agreement among studies utilizing the CPPD Ank mutations. This lack of consensus illustrates the limitations of in vitro systems, especially with respect to the availability of suitable in vitro model systems for the study of diseases of articular cartilage. Future studies of Ank mutations in animal models may illuminate the role of the CPPD-causing mutations on the transport of PPi and the pathological mineralization of articular cartilage.
In conclusion, we have stably transduced ATDC5 cells with wild-type and mutant cDNA ank constructs and have observed that, among the missense mutations, only the P5L mutant resulted in increased activity of NPP and resulted in increased elaboration of ePPi at the proliferative and nonmineralizing hypertrophic stages of differentiation. This effect was tempered during the mineralization phase when AP activity was high in all transduced cells.
We also observed that modest overexpression of ank may have subtle effects on chondrocyte maturation. Although this is the first report of a gain-of-function in one of the familial chondrocalcinosis-causing mutations, as previously hypothesized , it is not clear why the two other mutations in Ank (P5T and M48T) did not exhibit this effect. The increased ePPi elaboration in the P5L mutant appears to be driven by the excess NPP activity exhibited by this cell line (and other independent cell lines expressing this mutation). This observation may allude to the possibility of increased interaction between the P5L mutant molecule and NPP. The evidence for interaction between NPP and Ank is compelling [6, 35, 36]. Whether mutations in Ank may alter the affinity of potential interaction between these two proteins is intriguing and warrants further investigation.
It is also not clear at this time whether our observations reflect the state of ePPi elaboration in familial CPPD patients bearing mutations in ANKH. CPPD disease is a disease of articular cartilage that normally does not undergo mineralization, and several reports suggest that the pathological mineralization of articular cartilage in idiopathic chondrocalcinosis may occur in the context of hypertrophic differentiation [5, 25]. Interestingly, radiological examination of joints from familial CPPD disease patients indicates that crystal deposition precedes joint degeneration. Consequently, the state of articular cartilage differentiation with respect to markers of hypertrophy is unknown in patients suffering from familial chondrocalcinosis. Our observations of ePPi elaboration during the proliferative and nonmineralizing phases of chondrocyte hypertrophy may therefore hold some relevance in studies of the impact of ANKH mutations in dominantly inherited CPPD disease.
- ank :
= progressive ankylosis gene/cDNA (murine)
= progressive ankylosis protein (murine)
= progressive ankylosis protein (human)
= progressive ankylosis gene (human)
= alkaline phosphatase
= base pair
- col2a1 :
= gene coding for type II collagen (murine)
- col10a1 :
= gene coding for type X collagen (murine)
= calcium pyrophosphate dihydrate deposition
= Dulbecco's modified Eagle's medium
= enzyme-linked immunosorbent assay
= extracellular inorganic pyrophosphate
= intracellular inorganic pyrophosphate
= methionine position 48 to threonine
= nucleotide pyrophosphatase phosphodiesterase
= proline position 5 to leucine
= proline position 5 to threonine
= polymerase chain reaction
= inorganic pyrophosphate
= reverse transcriptase.
The authors gratefully acknowledge the excellent technical assistance of Gina Bonavita and Cheryl Starrett, and the advice of Dr David Coulter and Dr Sonsoles Piera-Velazquez for real-time PCR analyses. They also express gratitude to the staff of the Confocal Core Facility of the Kimmel Cancer Center at Thomas Jefferson University for confocal microscopy and to Dr Adele Boskey of the Hospital for Special Surgery for Fourier transform IR analyses. This work was supported by NIH/NIAMS grants AR44360 and AR052619 to CJW.
- Williams CJ: Familial calcium pyrophosphate dihydrate deposition disease and the ANKH gene [review, 43 refs]. Curr Opin Rheumatol. 2003, 15: 326-331. 10.1097/00002281-200305000-00023.View ArticlePubMedGoogle Scholar
- Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis.[see comment]. Science. 2000, 289: 265-270. 10.1126/science.289.5477.265.View ArticlePubMedGoogle Scholar
- Sohn P, Crowley M, Slattery E, Serra R: Developmental and TGF-β mediated regulation of Ank mRNA expression in cartilage and bone. Osteoarthritis Cartilage. 2002, 10: 482-490. 10.1053/joca.2002.0810.View ArticlePubMedGoogle Scholar
- Hirose J, Ryan LM, Masuda I: Up-regulated expression of cartilage intermediate-layer protein and ANK in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2002, 46: 3218-3229. 10.1002/art.10632.View ArticlePubMedGoogle Scholar
- Uzuki M, Ryan LM, Sawai T, Kingsley DM, Masuda I: Up-regulated expression of ANK in joint tissue from patients with calcium pyrophosphate dihydrate crystal deposition disease (CPPD) [abstract]. Arthritis Rheum. 2004, 50: S247-10.1002/art.11486.View ArticleGoogle Scholar
- Johnson K, Terkeltaub R: Upregulated ank expression in osteoarthritis can promote both chondrocyte MMP-13 expression and calcification via chondrocyte extracellular PPi excess. Osteoarthritis Cartilage. 2004, 12: 321-335. 10.1016/j.joca.2003.12.004.View ArticlePubMedGoogle Scholar
- Wang W, Xu J, Du B, Kirsch T: Role of the progressive ankylosis gene (ank) in cartilage mineralization. Mol Cell Biol. 2005, 25: 312-323. 10.1128/MCB.25.1.312-323.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Shukunami C, Ishizeki K, Atsumi T, Ohta Y, Suzuki F, Hiraki Y: Cellular hypertrophy and calcification of embryonal carcinoma-derived chondrogenic cell line ATDC5 in vitro. J Bone Miner Res. 1997, 12: 1174-1188. 10.1359/jbmr.19188.8.131.524.View ArticlePubMedGoogle Scholar
- Atsumi T, Miwa Y, Kimata K, Ikawa Y: A chondrogenic cell line derived from a differentiating culture of AT805 teratocarcinoma cells. Cell Differ Dev. 1990, 30: 109-116. 10.1016/0922-3371(90)90079-C.View ArticlePubMedGoogle Scholar
- Cham BE, Knowles BR: A solvent system for delipidation of plasma or serum without protein precipitation. J Lipid Res. 1976, 17: 176-181.PubMedGoogle Scholar
- Dion AS, Smorodinsky NI, Williams CJ, Wreschner DH, Major PP, Keydar I: Recognition of peptidyl epitopes by polymorphic epithelial mucin (PEM)-specific monoclonal antibodies. Hybridoma. 1991, 10: 595-610.View ArticlePubMedGoogle Scholar
- Lust G, Seegmiller JE: A rapid, enzymatic assay for measurement of inorganic pyrophosphate in biological samples. Clin Chim Acta. 1976, 66: 241-249. 10.1016/0009-8981(76)90061-9.View ArticlePubMedGoogle Scholar
- Johnson K, Vaingankar S, Chen Y, Moffa A, Goldring MB, Sano K, Jin-Hua P, Sali A, Goding J, Terkeltaub R: Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes. Arthritis Rheum. 1999, 42: 1986-1997. 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Tietz NW, Burtis CA, Duncan P, Ervin K, Petitclerc CJ, Rinker AD, Shuey D, Zygowicz ER: A reference method for measurement of alkaline phosphatase activity in human serum. Clin Chem. 1983, 29: 751-761.PubMedGoogle Scholar
- Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, et al: Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 2002, 71: 933-940. 10.1086/343054.PubMed CentralView ArticlePubMedGoogle Scholar
- Williams CJ, Pendleton A, Bonavita G, Reginato AJ, Hughes AE, Peariso S, Doherty M, McCarty DJ, Ryan LM: Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 2003, 48: 2627-2631. 10.1002/art.11133.View ArticlePubMedGoogle Scholar
- Williams CJ, Zhang Y, Timms A, Bonavita G, Caeiro F, Broxholme J, Cuthbertson J, Jones Y, Marchegiani R, Reginato A, et al: Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet. 2002, 71: 985-991. 10.1086/343053.PubMed CentralView ArticlePubMedGoogle Scholar
- Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, et al: Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001, 28: 37-41. 10.1038/88236.PubMedGoogle Scholar
- Reichenberger E, Tiziani V, Watanabe S, Park L, Uek Yi, Santanna C, Baur ST, Shiang R, Grange DK, Beighton P, et al: Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001, 68: 1321-1326. 10.1086/320612.PubMed CentralView ArticlePubMedGoogle Scholar
- Terkeltaub RA: Inorganic pyrophosphate generation and disposition in pathophysiology [review, 128 refs]. Am J Physiol Cell Physiol. 2001, 281: C1-C11.PubMedGoogle Scholar
- Hirose J, Masuda I, Ryan LM: Expression of cartilage intermediate layer protein/nucleotide pyrophosphohydrolase parallels the production of extracellular inorganic pyrophosphate in response to growth factors and with aging. Arthritis Rheum. 2000, 43: 2703-2711. 10.1002/1529-0131(200012)43:12<2703::AID-ANR10>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar
- Olmez U, Ryan LM, Kurup IV, Rosenthal AK: Insulin-like growth factor-1 suppresses pyrophosphate elaboration by transforming growth factor beta1-stimulated chondrocytes and cartilage. Osteoarthritis Cartilage. 1994, 2: 149-154. 10.1016/S1063-4584(05)80065-2.View ArticlePubMedGoogle Scholar
- Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millan JL: Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA. 2002, 99: 9445-9449. 10.1073/pnas.142063399.PubMed CentralView ArticlePubMedGoogle Scholar
- Johnson KA, Hessle L, Vaingankar S, Wennberg C, Mauro S, Narisawa S, Goding JW, Sano K, Millan JL, Terkeltaub R: Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol. 2000, 279: R1365-R1377.PubMedGoogle Scholar
- Rosenthal AK, Henry LA: Thyroid hormones induce features of the hypertrophic phenotype and stimulate correlates of CPPD crystal formation in articular chondrocytes. J Rheumatol. 1999, 26: 395-401.PubMedGoogle Scholar
- Iwamoto M, Shapiro IM, Yagami K, Boskey AL, Leboy PS, Adams SL, Pacifici M: Retinoic acid induces rapid mineralization and expression of mineralization-related genes in chondrocytes. Exp Cell Res. 1993, 207: 413-420. 10.1006/excr.1993.1209.View ArticlePubMedGoogle Scholar
- Lian JB, McKee MD, Todd AM, Gerstenfeld LC: Induction of bone-related proteins, osteocalcin and osteopontin, and their matrix ultrastructural localization with development of chondrocyte hypertrophy in vitro. J Cell Biochem. 1993, 52: 206-219. 10.1002/jcb.240520212.View ArticlePubMedGoogle Scholar
- Enomoto H, Enomoto-Iwamoto M, Iwamoto M, Nomura S, Himeno M, Kitamura Y, Kishimoto T, Komori T: Cbfa1 is a positive regulatory factor in chondrocyte maturation. J Biol Chem. 2000, 275: 8695-8702. 10.1074/jbc.275.12.8695.View ArticlePubMedGoogle Scholar
- Kim IS, Otto F, Zabel B, Mundlos S: Regulation of chondrocyte differentiation by Cbfa1. Mech Dev. 1999, 80: 159-170. 10.1016/S0925-4773(98)00210-X.View ArticlePubMedGoogle Scholar
- Zaka R, Williams CJ: Role of the progressive ankylosis gene in cartilage mineralization. Curr Opin Rheumatol. 2006, 18: 181-186. 10.1097/01.bor.0000209432.36355.6e.View ArticlePubMedGoogle Scholar
- Zhang Y, Johnson K, Russell G, Wordsworth P, Carr A, Terkeltaub RA, Brown MA: Association of sporadic chondrocalcinosis with a -4 basepair G to A transition in the 5' untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 2005, 52: 1110-1117. 10.1002/art.20978.View ArticlePubMedGoogle Scholar
- Yoshimatu T, Saitoh A, Ryu JN, Shima D, Hand H, Hiramoto M, Kawakami Y, Aizawa S: Characterization of immortalized human chondrocytes originated from osteoarthritic cartilage. Int J Mol Med. 2001, 8: 345-351.Google Scholar
- Ryan LM, Kurup I, Cheung HS: Stimulation of cartilage inorganic pyrophosphate elaboration by ascorbate. Matrix. 1991, 11: 276-281.View ArticlePubMedGoogle Scholar
- Bianchi A, Perrey J, Morin S, Moulin D, Koufany M, Gillet P, Loeuille D, Terlain B, Jouzeau J-Y, Netter P: Growth factors and cytokines modulate Progressive ankylosis gene expression in rat chondrocytes – Ank induction by TGFbeta depends on PKC pathway and ePPi level [abstract]. Arthritis Rheum. 2004, 50: S248-Google Scholar
- Johnson K, Goding J, Van Etten D, Sali A, Hsu SI, Farley D, Krug H, Hessle L, Millan JL, Terkeltaub R: Linked deficiencies in extracellular PPi and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003, 18: 994-1004. 10.1359/jbmr.2003.18.6.994.View ArticlePubMedGoogle Scholar
- Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL: Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1, and Ank. Am J Pathol. 2004, 164: 1199-1209.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.